Skip to main content
. 2017 Sep 11;7:11198. doi: 10.1038/s41598-017-10580-y

Figure 5.

Figure 5

TLR4 in human HaCat keratinocytes treated with LPS, a canonical activator of TLR4. Treatment with the solenopsin derivatives S12 and S14 led to a significant decrease in TLR4 expression. Cells were treated with solenopsin analogs (in DMSO) and/or primed with LPS (10 µg/ml) for 24 h.